Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
How does ZEJULA work?
Poly(ADP-ribose) polymerase (PARP) is a protein that plays a fundamental role in the detection and repair of DNA damage in cells,1 including damage induced by chemotherapy.2 ZEJULA is a PARP inhibitor, which works by inhibiting the repair of damaged DNA and inducing cell death.¹
Figure adapted from Konecny G, et al. 2016.3
Find out more
ZEJULA is indicated:1
- as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
- as monotherapy for the maintenance treatment of adult patients with platinum- based relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
References
- ZEJULA (niraparib) Summary of Product Characteristics. September 2025.
- Lei S, et al. Photodiagnosis Photodyn Ther. 2022;40:103058.
- Konecyny G, Kristeleit R. Br J Cancer. 2016;115(10):1157–1173.
- González Martín A, et al. N Engl J Med. 2019;381(25):2391–2402.
- Monk B, et al. Ann Oncol. 2024;35(11):981–992.
- Li N, et al. JAMA Oncol. 2023;9(9):1230–1237.
Abbreviations
1L, first-line; AOC, advanced ovarian cancer; DNA, deoxyribonucleic acid; FIGO, Federation of Gynaecology and Obstetrics; MoA, mechanism of action; PARPi, poly(ADP-ribose) polymerase inhibitor.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 4411 or UKSafety@gsk.com
February 2026 | PM-GB-NRP-WCNT-240007
